WASHINGTON, D.C. and NORWELL, Mass. — In a powerful display of unity and urgency, patients, caregivers, medical advocates, and leading clinicians converged on Capitol Hill on September 23, 2026, to shine a critical light on an often-overlooked public health crisis. Organized by the National Organization for Rare Disorders (NORD®) Rare Cancer Coalition® (RCC), the advocacy day was designed to draw national attention to the profound diagnosis, research, and treatment barriers confronting the staggering one in four cancer patients in the United States who are diagnosed with a rare form of the disease.
Throughout the day of action, participants engaged directly with federal lawmakers and legislative staff. Their primary message was clear and urgent: Congress must maintain and expand essential federal funding for the National Cancer Institute (NCI) and safeguard vital specialized programs like the Rare Cancers Research Program, which serves as a lifeline for patients who otherwise have virtually nowhere else to turn.
Rare cancers represent a remarkably broad and complex category of malignancies that includes every single pediatric cancer diagnosis. Despite making up a full quarter of all cancer diagnoses and subsequent deaths across the United States, rare cancers continue to face a severe systemic disadvantage. They remain chronically underfunded and understudied when compared to their more common counterparts.
These malignancies present distinct, formidable challenges to both patients and the medical community. Because patient populations for any single rare cancer are often extremely small, conducting large-scale clinical trials is exceptionally difficult. Furthermore, rare cancer patients routinely encounter severe barriers to receiving a timely and accurate diagnosis. These obstacles include limited physician familiarity with rare presentations, symptoms that frequently mimic much more common conditions, and persistent delays in securing appropriate pathology or advanced molecular and biomarker testing.
During their high-level meetings on Capitol Hill, rare cancer advocates emphasized the critical necessity of preserving an annual $17.5 million congressional earmark dedicated to the Rare Cancers Research Program. This crucial initiative is overseen by the Department of Defense Congressionally Directed Medical Research Program (CDMRP). Advocates urged continued, bipartisan congressional support to ensure this funding stream remains secure, enabling researchers to pursue clinically impactful discoveries that can translate directly into better outcomes for patients.
The advocacy efforts spanned across multiple key states. Throughout the day, delegates met with ten congressional offices representing rare cancer patient communities and research constituencies in Colorado, Massachusetts, Maryland, Michigan, and Virginia. These meetings provided a platform for participants to share their lived experiences and advocate for sustained, robust federal investment in specialized cancer research.
The delegation was composed of a diverse and dedicated group of stakeholders. Participants included Michael Beard, NORD’s Vice President of Federal and Global Public Policy, alongside four expert clinicians from Children’s National Hospital’s Pediatric Cancer Genetics Clinic. They were joined by six prominent member organizations of the NORD Rare Cancer Coalition: Jim Palma, Chief Executive Officer of the TargetCancer Foundation; Kristen Palma, President of the TargetCancer Foundation; Jeffery Kramer, President of the Chondrosarcoma Foundation; Ben Wilson, Chair of Community Engagement for the Bloom Syndrome Association; Elizabeth Accad, Community Engagement Manager of the Cutaneous Lymphoma Foundation; and Janet Thompson, Executive Director of the VHL Alliance.
Pam Gavin, Chief Executive Officer of NORD, underscored the heavy emotional and physical toll these systemic barriers take on American families.
“Too many families impacted by rare cancer endure a long path to diagnosis, often seeing multiple providers, struggling to find specialists with experience in their cancer and facing delays in specialized testing, only to discover that treatment options may be limited,” Gavin shared. “I am proud of the NORD Rare Cancer Coalition advocates who brought their experiences to Capitol Hill today to urge Congress to increase funding for the National Cancer Institute and advance rare cancer research.”

For many participants, the fight for increased research funding is deeply personal. Kristen Palma of Cambridge, Massachusetts, reflected on the profound isolation and devastation she and her family experienced years ago when her 38-year-old husband, Paul, was diagnosed with a rare cancer that offered virtually no established treatment options.
“Rare Cancer Day is a day to recognize a community of patients and families who are too often overlooked while acknowledging their unique challenges and needs. And it is a day to commit to action,” Palma said. “I remember how isolated, devastated and terrified we felt when we learned that my 38-year-old husband Paul’s cancer was rare and had no treatment options. Rare Cancer Day did not exist then, there was not a community for us to turn to, and dollars were not being spent to discover treatments for a cancer like his.”
Palma emphasized that the landscape has shifted significantly over the years, largely due to targeted federal investments, and stressed that current progress must not be allowed to stall.
“The discoveries made through grants supported by the Department of Defense CDMRP Rare Cancer Program are directly impacting patients today, giving time to families that we never had,” she added. “We have come so far since then and cannot let that momentum slow down, even for a moment.”
The national conversation surrounding rare diseases and rare cancers will continue next month in Washington, D.C., at NORD’s 2026 Rare Disease & Orphan Products Breakthrough Summit®. The major conference is expected to draw more than 900 rare disease stakeholders from across the healthcare, research, and regulatory sectors. Attendees will convene to address shared, systemic challenges spanning timely diagnosis, foundational research, innovative drug development, and equitable patient access to specialized care, including the specific hurdles facing those diagnosed with rare forms of cancer.
The NORD Rare Cancer Coalition was formalized in 2017 as a specialized program under the broader NORD membership umbrella. Today, the coalition brings together 30 distinct rare cancer-specific patient advocacy organizations with the unified goal of improving clinical and quality-of-life outcomes for rare cancer patients. Through coordinated awareness campaigns, targeted research initiatives, educational programs, and legislative advocacy, the coalition strives to bring visibility to an underserved community.
In 2019, the Rare Cancer Coalition established Rare Cancer Day as an annual observance to unite the rare cancer community, heighten public awareness regarding the unique obstacles patients and their families face, and accelerate momentum toward earlier diagnoses and more effective treatments. Beginning in 2026, Rare Cancer Day is officially recognized on September 23, marking a strategic shift from its previous observance on September 30.
Founded in 1983, the National Organization for Rare Disorders remains the leading independent, nonpartisan, nonprofit organization dedicated to improving the health and well-being of the more than 30 million Americans living with rare diseases. Working hand in hand with over 350 disease-specific member patient organizations, NORD continues to drive meaningful progress in rare disease research, clinical care, and public policy at both the federal and state levels.
